It is noteworthy that there is evidence from randomized clinical trials of better in-hospital outcomes in COVID-19 patients treated with either tocilizumab or anti-PCSK9 monoclonal antibodies [49,50,51], which are recognized pharmacological strategies with the ability to reduce Lp(a) levels by ~30% beyond their main therapeutic effects [52,53]; however, no data are available on the relationship between Lp(a) reduction by either tocilizumab or anti-PCSK9 monoclonal antibodies and the clinical outcomes of patients hospitalized for COVID-19 [49,50,51]. Here, PCSK9 is linked to COVID-19.